Orion's Operating Profits Hit By Generic Competition

News: Finland-based Orion's operating profit in Q313 has dropped 12% year-on-year (y-o-y) to EUR67mn (US$91.6mn), from EUR76mn (US$103.90mn) in Q312. The company has attributed the decline to more competitive generic market prices following the expiration of the patents of its Parkinson's drug. The company's overall sales in Q313 also declined 4% y-o-y to EUR237mn (US$324.01mn), which stood below the expected sales of EUR245mn (US$334.95mn).

Orion's Operating Profits Hit By Generic Competition

News: Finland-based Orion's operating profit in Q313 has dropped 12% year-on-year (y-o-y) to EUR67mn (US$91.6mn), from EUR76mn (US$103.90mn) in Q312. The company has attributed the decline to more competitive generic market prices following the expiration of the patents of its Parkinson's drug. The company's overall sales in Q313 also declined 4% y-o-y to EUR237mn (US$324.01mn), which stood below the expected sales of EUR245mn (US$334.95mn).

×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

×

REQUEST A DEMO

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.